Health Trials

Study of the Disease Process of Lymphangioleiomyomatosis

ConditionsLung DiseasePneumothoraxTuberous SclerosisLymphangioleiomyomatosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-100
SponsorNational Heart, Lung, and Blood Institute (NHLBI)

About this trial

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.

This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy.

Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Toshibia Aquilion One CT

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Lead sponsor

Source ClinicalTrials.gov